Skip to main content
Erschienen in: Journal of Neuro-Oncology 1/2019

11.12.2018 | Laboratory Investigation

MiR-101-3p inhibits EMT to attenuate proliferation and metastasis in glioblastoma by targeting TRIM44

Erschienen in: Journal of Neuro-Oncology | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Glioblastoma (GBM) is the most common malignant tumor originating in the brain parenchyma. The invasive and infiltrative properties of glioblastoma result in poor clinical prognosis to conventional therapies. Emerging reports on microRNAs as important regulators during the process of EMT provide new insights into treating glioblastoma through new targets. However, underlying molecular mechanism of the regulation of miR-101-3p in glioblastoma remains unclear.

Methods

Level of miR-101-3p was determined in GBM cell lines by qRT-PCR. MTT, colony formation and transwell assays were utilized to evaluate functions of overexpression of miR-101-3p/knock down of TRIM44 on proliferation, migration and invasion in GBM cells. Direct interaction between miR-101-3p and TRIM44 was validated using dual luciferase reporter system and impacts of overexpression of miR-101-3p/knock down of TRIM44 on regulation of EMT markers were assessed by Western blotting.

Results

MiR-101-3p was validated to be repressed expressed in glioblastoma cancer cell lines. Both overexpression of miR-101-3p and knock down of TRIM44 attenuated proliferation, migration and invasion of glioblastoma cell lines in vitro. TRIM44 was shown to promote EMT in GBM progress and reverse inhibitory function of miR-101-3p. MiR-101-3p was found to suppress the expression of TRIM44 via directly targeting its 3′UTR.

Conclusions

Our findings suggested miR-101-3p regulated proliferation and migration of glioblastoma cells through attenuating TRIM44 induced EMT via direct targeting 3′UTR of TRIM44, which provided preliminary study of potential therapeutic target in future GBM treatment.
Literatur
1.
2.
Zurück zum Zitat Louis DN et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820CrossRefPubMed Louis DN et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820CrossRefPubMed
3.
Zurück zum Zitat Quick A et al (2010) Current therapeutic paradigms in glioblastoma. Rev Recent Clin Trials 5(1):14–27CrossRefPubMed Quick A et al (2010) Current therapeutic paradigms in glioblastoma. Rev Recent Clin Trials 5(1):14–27CrossRefPubMed
4.
Zurück zum Zitat Iser IC et al (2017) The epithelial-to-mesenchymal transition-like process in glioblastoma: an updated systematic review and in silico investigation. Med Res Rev 37(2):271–313CrossRefPubMed Iser IC et al (2017) The epithelial-to-mesenchymal transition-like process in glioblastoma: an updated systematic review and in silico investigation. Med Res Rev 37(2):271–313CrossRefPubMed
5.
Zurück zum Zitat Mahabir R et al (2014) Sustained elevation of Snail promotes glial-mesenchymal transition after irradiation in malignant glioma. Neuro Oncol 16(5):671–685CrossRefPubMed Mahabir R et al (2014) Sustained elevation of Snail promotes glial-mesenchymal transition after irradiation in malignant glioma. Neuro Oncol 16(5):671–685CrossRefPubMed
6.
Zurück zum Zitat Liao H et al (2015) MiR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2. Oncotarget 6(11):8914–8928CrossRefPubMedPubMedCentral Liao H et al (2015) MiR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2. Oncotarget 6(11):8914–8928CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Ying Xing QM, Chen X, Zhao Y, Liu W, Jing, Hu, Feng, Xue XW, Cai L (2016) TRIM44 promotes proliferation and metastasis in non-small cell. Oncotarget 7(21):30479–30491CrossRefPubMedPubMedCentral Ying Xing QM, Chen X, Zhao Y, Liu W, Jing, Hu, Feng, Xue XW, Cai L (2016) TRIM44 promotes proliferation and metastasis in non-small cell. Oncotarget 7(21):30479–30491CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Li Q et al (2016) MicroRNA-663 inhibits the proliferation, migration and invasion of glioblastoma cells via targeting TGF-beta1. Oncol Rep 35(2):1125–1134CrossRefPubMed Li Q et al (2016) MicroRNA-663 inhibits the proliferation, migration and invasion of glioblastoma cells via targeting TGF-beta1. Oncol Rep 35(2):1125–1134CrossRefPubMed
9.
Zurück zum Zitat Chen W et al (2018) Downregulation of miR205 is associated with glioblastoma cell migration, invasion, and the epithelial-mesenchymal transition, by targeting ZEB1 via the Akt/mTOR signaling pathway. Int J Oncol 52(2):485–495PubMed Chen W et al (2018) Downregulation of miR205 is associated with glioblastoma cell migration, invasion, and the epithelial-mesenchymal transition, by targeting ZEB1 via the Akt/mTOR signaling pathway. Int J Oncol 52(2):485–495PubMed
10.
Zurück zum Zitat Ma C et al (2017) MicroRNA-10b mediates TGF-beta1-regulated glioblastoma proliferation, migration and epithelial-mesenchymal transition. Int J Oncol 50(5):1739–1748CrossRefPubMed Ma C et al (2017) MicroRNA-10b mediates TGF-beta1-regulated glioblastoma proliferation, migration and epithelial-mesenchymal transition. Int J Oncol 50(5):1739–1748CrossRefPubMed
11.
Zurück zum Zitat Yan Y et al (2015) miR-10a controls glioma migration and invasion through regulating epithelial-mesenchymal transition via EphA8. FEBS Lett 589(6):756–765CrossRefPubMed Yan Y et al (2015) miR-10a controls glioma migration and invasion through regulating epithelial-mesenchymal transition via EphA8. FEBS Lett 589(6):756–765CrossRefPubMed
12.
Zurück zum Zitat Smits M et al (2010) miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis. Oncotarget 1(8):710–720CrossRefPubMed Smits M et al (2010) miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis. Oncotarget 1(8):710–720CrossRefPubMed
13.
Zurück zum Zitat Xiaoping L et al (2013) CPEB1, a histone-modified hypomethylated gene, is regulated by miR-101 and involved in cell senescence in glioma. Cell Death Dis 4:e675CrossRefPubMedPubMedCentral Xiaoping L et al (2013) CPEB1, a histone-modified hypomethylated gene, is regulated by miR-101 and involved in cell senescence in glioma. Cell Death Dis 4:e675CrossRefPubMedPubMedCentral
15.
16.
Zurück zum Zitat Liu N et al (2017) MicroRNA-101 inhibits proliferation, migration and invasion of human glioblastoma by targeting SOX9. Oncotarget 8(12):19244–19254CrossRefPubMed Liu N et al (2017) MicroRNA-101 inhibits proliferation, migration and invasion of human glioblastoma by targeting SOX9. Oncotarget 8(12):19244–19254CrossRefPubMed
17.
Zurück zum Zitat Hatakeyama S, Family Proteins TRIM (2017) Roles in autophagy, immunity, and carcinogenesis. Trends Biochem Sci 42(4):297–311CrossRefPubMed Hatakeyama S, Family Proteins TRIM (2017) Roles in autophagy, immunity, and carcinogenesis. Trends Biochem Sci 42(4):297–311CrossRefPubMed
20.
Zurück zum Zitat Kawabata H et al. (2017) TRIM44 is a poor prognostic factor for breast cancer patients as a modulator of NF-kappaB signaling. Int J Mol Sci 18(9):1931CrossRefPubMedPubMedCentral Kawabata H et al. (2017) TRIM44 is a poor prognostic factor for breast cancer patients as a modulator of NF-kappaB signaling. Int J Mol Sci 18(9):1931CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Xing Y et al (2016) TRIM44 promotes proliferation and metastasis in nonsmall cell lung cancer via mTOR signaling pathway. Oncotarget 7(21):30479–30491CrossRefPubMedPubMedCentral Xing Y et al (2016) TRIM44 promotes proliferation and metastasis in nonsmall cell lung cancer via mTOR signaling pathway. Oncotarget 7(21):30479–30491CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Zhou Z et al (2017) Knockdown of TRIM44 inhibits the proliferation and invasion in papillary thyroid cancer cells through suppressing the Wnt/beta-catenin signaling pathway. Biomed Pharmacother 96:98–103CrossRefPubMed Zhou Z et al (2017) Knockdown of TRIM44 inhibits the proliferation and invasion in papillary thyroid cancer cells through suppressing the Wnt/beta-catenin signaling pathway. Biomed Pharmacother 96:98–103CrossRefPubMed
23.
Zurück zum Zitat Yamada Y et al (2017) A novel prognostic factor TRIM44 promotes cell proliferation and migration, and inhibits apoptosis in testicular germ cell tumor. Cancer Sci 108(1):32–41CrossRefPubMed Yamada Y et al (2017) A novel prognostic factor TRIM44 promotes cell proliferation and migration, and inhibits apoptosis in testicular germ cell tumor. Cancer Sci 108(1):32–41CrossRefPubMed
24.
Zurück zum Zitat Peng R et al. (2018) Elevated TRIM44 promotes intrahepatic cholangiocarcinoma progression by inducing cell EMT via MAPK signaling. Cancer Med 7:796–808CrossRef Peng R et al. (2018) Elevated TRIM44 promotes intrahepatic cholangiocarcinoma progression by inducing cell EMT via MAPK signaling. Cancer Med 7:796–808CrossRef
25.
Zurück zum Zitat Ostrom QT et al (2014) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol 16(Suppl 4):iv1–i63CrossRefPubMedPubMedCentral Ostrom QT et al (2014) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol 16(Suppl 4):iv1–i63CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Gui T, Shen K (2012) miRNA-101: a potential target for tumor therapy. Cancer Epidemiol 36(6):537–540CrossRefPubMed Gui T, Shen K (2012) miRNA-101: a potential target for tumor therapy. Cancer Epidemiol 36(6):537–540CrossRefPubMed
27.
Zurück zum Zitat Zhao S et al (2015) Loss of microRNA-101 promotes epithelial to mesenchymal transition in hepatocytes. J Cell Physiol 230(11):2706–2717CrossRefPubMed Zhao S et al (2015) Loss of microRNA-101 promotes epithelial to mesenchymal transition in hepatocytes. J Cell Physiol 230(11):2706–2717CrossRefPubMed
28.
Zurück zum Zitat Ye Z et al (2016) Downregulation of miR-101 contributes to epithelial-mesenchymal transition in cisplatin resistance of NSCLC cells by targeting ROCK2. Oncotarget 7(25):37524–37535CrossRefPubMedPubMedCentral Ye Z et al (2016) Downregulation of miR-101 contributes to epithelial-mesenchymal transition in cisplatin resistance of NSCLC cells by targeting ROCK2. Oncotarget 7(25):37524–37535CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Guo F et al (2014) MiR-101 suppresses the epithelial-to-mesenchymal transition by targeting ZEB1 and ZEB2 in ovarian carcinoma. Oncol Rep 31(5):2021–2028CrossRefPubMedPubMedCentral Guo F et al (2014) MiR-101 suppresses the epithelial-to-mesenchymal transition by targeting ZEB1 and ZEB2 in ovarian carcinoma. Oncol Rep 31(5):2021–2028CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Zheng M et al (2015) Snail and Slug collaborate on EMT and tumor metastasis through miR-101-mediated EZH2 axis in oral tongue squamous cell carcinoma. Oncotarget 6(9):6797–6810CrossRefPubMed Zheng M et al (2015) Snail and Slug collaborate on EMT and tumor metastasis through miR-101-mediated EZH2 axis in oral tongue squamous cell carcinoma. Oncotarget 6(9):6797–6810CrossRefPubMed
31.
Zurück zum Zitat Jiang W et al (2016) miRNA-101 suppresses epithelial-to-mesenchymal transition by targeting HMGA2 in pancreatic cancer cells. Anticancer Agents Med Chem 16(4):432–439CrossRefPubMed Jiang W et al (2016) miRNA-101 suppresses epithelial-to-mesenchymal transition by targeting HMGA2 in pancreatic cancer cells. Anticancer Agents Med Chem 16(4):432–439CrossRefPubMed
32.
Zurück zum Zitat Chandra Mangalhara K et al (2017) ERK2-ZEB1-miR-101-1 axis contributes to epithelial-mesenchymal transition and cell migration in cancer. Cancer Lett 391:59–73CrossRefPubMed Chandra Mangalhara K et al (2017) ERK2-ZEB1-miR-101-1 axis contributes to epithelial-mesenchymal transition and cell migration in cancer. Cancer Lett 391:59–73CrossRefPubMed
33.
Zurück zum Zitat Cui Y et al (2017) Upregulated lncRNA SNHG1 contributes to progression of non-small cell lung cancer through inhibition of miR-101-3p and activation of Wnt/beta-catenin signaling pathway. Oncotarget 8(11):17785–17794CrossRefPubMedPubMedCentral Cui Y et al (2017) Upregulated lncRNA SNHG1 contributes to progression of non-small cell lung cancer through inhibition of miR-101-3p and activation of Wnt/beta-catenin signaling pathway. Oncotarget 8(11):17785–17794CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Chen W et al (2017) MALAT1-miR-101-SOX9 feedback loop modulates the chemo-resistance of lung cancer cell to DDP via Wnt signaling pathway. Oncotarget 8(55):94317–94329CrossRefPubMedPubMedCentral Chen W et al (2017) MALAT1-miR-101-SOX9 feedback loop modulates the chemo-resistance of lung cancer cell to DDP via Wnt signaling pathway. Oncotarget 8(55):94317–94329CrossRefPubMedPubMedCentral
Metadaten
Titel
MiR-101-3p inhibits EMT to attenuate proliferation and metastasis in glioblastoma by targeting TRIM44
Publikationsdatum
11.12.2018
Erschienen in
Journal of Neuro-Oncology / Ausgabe 1/2019
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-018-2973-7

Weitere Artikel der Ausgabe 1/2019

Journal of Neuro-Oncology 1/2019 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Vierten reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.